Teriparatide

Teriparatide is recombinant human parathyroid hormone 1-34, an anabolic osteoporosis medicine studied in large randomized trials and supported by regulatory labeling. Unlike antiresorptive osteoporosis drugs, intermittent teriparatide stimulates bone formation. In postmenopausal women with osteoporosis, a pivotal randomized trial found reduced vertebral and nonvertebral fracture risk and increased bone mineral density. Teriparatide is also labeled for increasing bone mass in men with primary or hypogonadal osteoporosis at high fracture risk and for osteoporosis associated with sustained systemic glucocorticoid therapy. Claims should stay within approved-label indications and major trial endpoints, without extrapolating to performance, anti-aging, or nonmedical bone-building claims.

Osteoporosis Trial Evidence

Teriparatide reduced vertebral and nonvertebral fractures and increased bone mineral density in a pivotal postmenopausal osteoporosis trial ^[1].

Regulatory Indications

FDA labeling supports use for specific high-fracture-risk osteoporosis populations, including postmenopausal women, men with primary or hypogonadal osteoporosis, and glucocorticoid-associated osteoporosis ^[2].

Glucocorticoid-Induced Osteoporosis

Randomized comparisons with alendronate showed greater lumbar spine bone mineral density gains and fewer new vertebral fractures in teriparatide-treated participants ^[3][4].

Label Warnings

Labeling discusses osteosarcoma-related precautions, hypercalcemia, cutaneous calcification including calciphylaxis, orthostatic hypotension, urolithiasis considerations, and use limits when fracture risk remains high ^[2].

Claim Limits

Teriparatide should not be presented as a performance, anti-aging, or nonmedical bone-building product ^[2].